Aimovig (erenumab-aooe) / Amgen, Novartis - LARVOL DELTA

Migraine treatment with CGRP monoclonal antibodies: patient evaluation of a mandatory treatment holiday in Belgium. (PubMed, Acta Neurol Belg) - "A rigid, mandatory treatment holiday of two to three months poses significant challenges for a substantial subset of patients, leading to rapid migraine deterioration and increased anxiety. The observed association between migraine deterioration and anxiety highlights the need for patient education strategies. Policy makers should consider these findings to develop more flexible, patient-centered treatment approaches that optimize outcomes."

Journal • CNS Disorders • Migraine • Mood Disorders • Pain • Psychiatry

The Optimum Dose of Erenumab to Improve Quality of Life in Patients with Episodic Migraines: A Systematic Review, Meta-analysis and Network Meta-analysis. (P10-12.005). (PubMed, Neurology) - "Dr. Alavinia has nothing to disclose."

Clinical • HEOR • Journal • Retrospective data • Review • CNS Disorders • Migraine • Pain

Successful Management of Wearing-off effect with Eptinezumab: Lessons from a case with Chronic Migraine Refractory to Two Subcutaneous CGRP Antibodies (PubMed, Rev Neurol) - "She failed to respond to multiple oral preventatives, botulinum toxin, and two CGRP antibodies (erenumab and galcanezumab). Conclusions CGRP antibodies can show a wearing-off effect, which should be identified in order to plan individualized treatment and avoid an incorrect interpretation as therapeutic failure. Our case also shows that patients with chronic migraine refractory to two antibodies can respond to a third CGRP antibody, in this case, intravenous eptinezumab."

Journal • CNS Disorders • Migraine • Pain

A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland. (PubMed, Pain Ther) - "Patient experiences of using subcutaneous CGRP mAbs in Finland showed improvements in several migraine-related factors, supporting the potential for CGRP mAbs to improve the quality of life of adults with migraine."

Journal • Real-world evidence • CNS Disorders • Migraine • Pain

Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH (clinicaltrials.gov) - P2 | N=112 | Active, not recruiting | Sponsor: Mayo Clinic | Recruiting ➔ Active, not recruiting

Enrollment closed • Pain

Quickest way to less headache days: an operational research model and its implementation for chronic migraine. (PubMed, BMC Neurol) - "We propose an optimal sequence for preventive medication trial for patients with chronic migraine. Since our model makes limited assumptions on the characteristics of disease, it can be readily applied also to episodic migraine, given the appropriate data as input. Indeed, our model can be applied to other scenarios so long as probability of success/adverse event as a function of time can be estimated. As such, we believe our model may have implications beyond our sub-specialty."

Journal • CNS Disorders • Migraine • Pain

Health care resource utilization and direct costs incurred over 12 months by patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibodies: A US real-world study. (PubMed, J Manag Care Spec Pharm) - "HCRU and direct cost differences observed at 12 months following initiation of self-injectable CGRP mAbs for migraine prevention were numerically similar across cohorts for patients treated with galcanezumab, fremanezumab, and erenumab. More work should be done to learn if these drugs perform differently with respect to other important factors not examined here."

HEOR • Journal • Real-world evidence • Retrospective data • CNS Disorders • Migraine • Pain

Cost-Utility Analysis of Migraine Prevention Treatments for Chronic Migraine Headaches Patients in the United States (ISPOR 2025) - "OBJECTIVES: To evaluate the cost-effectiveness of migraine prevention treatments in patients with chronic migraine A hybrid decision-Markov model was constructed to evaluate the cost-effectiveness of prevention medications (eptinezumab, erenumab, and onabotulinumtoxinA) for chronic migraine. Eptinezumab was a cost-effective strategy at a WTP of $50,000 per QALY gained compared to onabotulinumtoxinA. However, onabotulinumtoxinA may be an alternative cost-effective option if eptinezumab was not tolerated by the patient."

Clinical • HEOR • CNS Disorders • Migraine • Pain

Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis. (PubMed, Head Face Med) - "This meta-analysis found that Erenumab significantly reduced migraine attack frequency, medication days, and physical impairment. It was more effective for patients with prior treatment failures. The 140 mg dose showed better MSMD reduction than 70 mg. Erenumab's safety profile was similar to that of placebo, with only constipation noted as significant."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Migraine • Pain

Efficacy and safety of mAbs anti-CGRP/CGRP R (eptinezumab and erenumab) or atogepant in combination with onabotulinumtoxinA in refractory chronic migraine: a clinical trial protocol. (PubMed, Pain Manag) - "Chronic migraine is a disabling neurovascular disorder that represents the leading cause of years lived with disability in people under 50 with a remarkable social burden due to widespread resistance to the front-line treatments used routinely in current clinical practice. Furthermore, a feasible salivary biomarker of migraine is under investigation in the prospective stage of the study. Based on recent expert opinions supporting the switch to easy-to-use small molecule calcitonin gene-related peptide (CGRP)-targeting, i.e. rimegepant or atogepant in unresponsive patients, the present study may offer to clinicians a novel treatment to enhance the therapeutic preventive machinery in chronic migraine."

Journal • CNS Disorders • Migraine • Pain

Patient satisfaction with calcitonin gene-related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study. (PubMed, Headache) - "Most patients were satisfied with CGRP mAbs' effectiveness, tolerability, and convenience in a real-world setting. Interestingly, increasing TS was associated with meaningful reductions in frequency, impact, and disability caused by migraine."

Journal • CNS Disorders • Migraine • Pain

CROATIAN GUIDELINES FOR SPECIFIC PREVENTIVE TREATMENT OF MIGRAINE WITH MONOCLONAL ANTIBODIES TARGETING CALCITONIN GENE-RELATED PEPTIDE (CGRP) (EPTINEZUMAB, FREMANEZUMAB, AND GALCANEZUMAB) OR THE CGRP RECEPTOR (ERENUMAB). (PubMed, Acta Clin Croat) - "These medications may be considered as first-line prophylactic therapy depending on the patient's history, concomitant diseases, and disease burden. Further real-world studies are needed to elucidate other aspects of their application."

Clinical guideline • Journal • Review • CNS Disorders • Inflammation • Migraine • Pain

Erenumab treatment results at our hospital (JSNE 2025) - No abstract available

Clinical • CNS Disorders • Migraine • Pain

Ubrogepant, erenumab, and eptinezumab antagonize positive inotropic effects of the calcitonin gene-related peptide in the isolated human atrium. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "In a more effective way, 1 µM carbachol and 1 µM (-)-N6-phenylisopropyladenosine (PIA) attenuated the PIE of CGRP in the presence of cilostamide. We conclude that ubrogepant, erenumab, and eptinezumab are functional antagonists of CGRP in HAP at therapeutic concentrations of these anti-migraine drugs. Further investigation is necessary to determine whether this reduction in FOC is beneficial or detrimental for migraine patients."

Journal • CNS Disorders • Migraine • Pain

UnitedHealth eases rules on renewing some prescription drugs (Yahoo Finance) - "UnitedHealth Group's pharmacy benefit manager, Optum Rx, said on Wednesday it would ease requirements to get insurance authorization when renewing prescriptions on about 80 drugs, aiming to reduce paperwork for patients and doctors...The list, which could be expanded over time, will eliminate up to 25% of reauthorization requirements and accounts for more than 10% of all such pharmacy authorizations, it said....The program starts on May 1 and will include drugs ranging from Amgen's migraine treatment Aimovig, Vertex Pharmaceutical's cystic fibrosis treatment Kalydeco, and Regeneron's Praluent for high cholesterol."

Reimbursement • Cystic Fibrosis • Metabolic Disorders • Migraine

Assessing blood pressure changes and hypertension-related outcomes in patients with migraine treated with erenumab: A systematic review and meta-analysis. (PubMed, Headache) - "We did not find an association of erenumab with significant increases in systemic BP. There is a considerable degree of fragility in the current evidence available. The decision to prescribe erenumab, especially for patients with multiple comorbidities and risk factors for hypertension, must be made weighing the risks and benefits. Further studies are needed to confirm these findings."

Journal • Retrospective data • Review • Cardiovascular • CNS Disorders • Hypertension • Migraine • Pain

Efficacy and continuability of 675 mg fremanezumab administration over 2 years. (PubMed, J Headache Pain) - "Fremanezumab 675 mg quarterly dose effectively reduces headache frequency over an extended period and may facilitate medication cessation in patients who experience substantial recovery."

Journal • Observational data • CNS Disorders • Dermatology • Migraine • Pain

Comparison of different treatment strategies for medication overuse headache: a systematic review and meta-analysis (AAN 2025) - "A total of 10 randomized controlled trials and 3925 patients were included, of whom 2786 (70,98%) received monoclonal antibodies and 562 (14,3%) received botulinum toxin A, including erenumab, fremanezumab, and eptinezumab for both MOH and migraine treatments. In this meta-analysis, we concluded that both monoclonal antibodies and botulinum toxin A injections effectively achieved monthly headache and monthly migraine reductions."

Retrospective data • Review • CNS Disorders • Migraine • Pain

Efficacy and Safety of Erenumab for Chronic Migraine and Medication Overuse: A Comprehensive Systematic Review and Single Arm Meta-Analysis (AAN 2025) - "Erenumab may effectively reduce migraine frequency and medication use in CM-MOH patients with a manageable safety profile. It substantially improves the likelihood of achieving meaningful migraine relief, making it a valuable preventive option for this difficult-to-treat population."

Retrospective data • Review • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Migraine • Pain

The Optimum Dose of Erenumab to Improve Quality of Life in Patients with Episodic Migraines: A Systematic Review, Meta-analysis and Network Meta-analysis. (AAN 2025) - "The results of our network meta-analysis suggest that, while erenumab either at 70mg or 140mg similarly decrease the monthly migraine days, only erenumab at 140mg significantly improved quality of life as assessed using HIT-6 when compared with erenumab 70mg and placebo."

HEOR • Retrospective data • Review • CNS Disorders • Migraine • Pain

Assessing Blood Pressure Changes and Hypertension-Related Outcomes in Patients with Migraine Treated with Erenumab: a Systematic Review and Single-Arm Meta-Analysis (AAN 2025) - "We did not find an association of erenumab with an increased BP. However, there is considerable uncertainty in the current evidence. The decision to prescribe erenumab, especially for patients with multiple comorbidities, must be made weighing up risks and benefits."

Retrospective data • Review • Cardiovascular • CNS Disorders • Hypertension • Migraine • Pain

The Efficacy and Safety of Erenumab in Patients with Migraine: A Systematic Review and Meta-Analysis (AAN 2025) - "Erenumab significantly reduced migraine attacks and medication use, especially in patients with previous treatment failures. The 140 mg dose was more effective than 70 mg for reducing MSMD, with a safety profile similar to placebo."

Retrospective data • Review • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Migraine • Pain

Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database-based observational cohort study. (PubMed, Headache) - "In this analysis of the MarketScan medical claims database, we found no difference in the risk of vascular events in patients treated with erenumab versus other anti-CGRP pathway mAbs or onabotulinumtoxinA."

Journal • Observational data • Cardiovascular • CNS Disorders • Hypertension • Migraine • Myocardial Infarction • Pain

Aimovig: Expiry of patents related to CGRP receptor antibodies in EU on Dec 18, 2029 and in US on May 17, 2032 (Amgen) - Annual Report 2024: Expiry of patents related to methods of treatment in EU on Aug 10, 2035 and US on Apr 22, 2036; SPC in France, Italy and Spain and UK until 2033, Expiry of patents related to compositions and pharmaceutical formulations in US on Apr 1, 2039

Patent • CNS Disorders • Migraine • Pain

Real-world adherence to erenumab, rescue medication utilization, and work absenteeism for patients with migraine: Results from an outcomes-based agreement. (PubMed, J Manag Care Spec Pharm) - "The inclusion of a work outcomes cohort provided valuable insights about the clinical benefits of erenumab for migraine prevention. Our findings provide additional insights on the real-world use of erenumab within the context of an outcomes-based agreement."

HEOR • Journal • Real-world evidence • CNS Disorders • Infectious Disease • Migraine • Novel Coronavirus Disease • Pain